研究業績
-
2024年01月04日Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility.
-
2024年01月04日Type-I interferon delivery by iPSC-derived myeloid cells elicits antitumor immunity via XCR1+ dendritec cells.
-
2024年01月04日Developing thymus-on-a-chip and cancer-on-a-chip for cancer immunotherapy.
-
2024年01月04日iPS細胞技術を用いたがん免疫療法
-
2024年01月04日Toward the development of true “off-the-shelf” synthetic T-cell immunotherapy.
-
2024年01月04日Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy.
-
2024年01月04日Generation of HIV-resistant macrophages from iPSCs by using transcriptional gene silencing and promoter-targeted RNA.
-
2024年01月04日Repurposing the cord blood bank for haplobanking of HLA-homozygous iPSCs and their usefulness to multiple populations.
-
2024年01月04日Generation of TCR expressing innate lymphoid helper cells that induces cytotoxic T cell-mediated anti-leukemic immunity in HLA class-II and BCR-ABL peptide restriction.
-
2024年01月04日Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors.
-
2024年01月04日A revised road map for the commitment of human cord-blood CD340negative hematopoietic stem cells.
-
2024年01月04日iPS細胞技術を応用したがん免疫療法－幹細胞生物学、腫瘍免疫学、遺伝子治療学の融合が生み出しつつあるもの－
